Dapagliflozin for Atrial Fibrillation

Springer Science and Business Media LLC - Trang 1-3 - 2024
Na Li1, Mihail G. Chelu2, Yochai Birnbaum2
1Department of Medicine, Section of Cardiovascular Research, Baylor College of Medicine, Houston, USA
2Department of Medicine, Section of Cardiology, Baylor College of Medicine, Houston, USA

Tài liệu tham khảo

Zelniker TA, Bonaca MP, Furtado RHM, et al. Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 Trial. Circulation. 2020;141(15):1227–34. https://doi.org/10.1161/CIRCULATIONAHA.119.044183.

Luo F, Sun L, Wang Z, et al. Effect of dapagliflozin on the outcome of radiofrequency catheter ablation in patients with type 2 diabetes mellitus and atrial fibrillation. Cardiovasc Drugs Ther. 2024;38(1). https://doi.org/10.1007/s10557-022-07368-2.

Kishima H, Mine T, Fukuhara E, et al. Efficacy of sodium-glucose cotransporter 2 inhibitors on outcomes after catheter ablation for atrial fibrillation. JACC Clin Electrophysiol. 2022;8(11):1393–404. https://doi.org/10.1016/j.jacep.2022.08.004.

Abu-Qaoud MR, Kumar A, Tarun T, et al. Impact of SGLT2 inhibitors on AF recurrence after catheter ablation in patients with type 2 diabetes. JACC Clin Electrophysiol. 2023;9(10):2109–18. https://doi.org/10.1016/j.jacep.2023.06.008.

Ye Y, Bajaj M, Yang HC, Perez-Polo JR, Birnbaum Y. SGLT-2 Inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. Cardiovasc Drugs Ther. 2017;31(2):119–32. https://doi.org/10.1007/s10557-017-6725-2.

Ryaboshapkina M, Ye R, Ye Y, Birnbaum Y. Effects of dapagliflozin on myocardial gene expression in BTBR mice with type 2 diabetes. Cardiovasc Drugs Ther. 2023. https://doi.org/10.1007/s10557-023-07517-1.

Scisciola L, Chianese U, Caponigro V, et al. Multi-omics analysis reveals attenuation of cellular stress by empagliflozin in high glucose-treated human cardiomyocytes. J Transl Med. 2023;21(1):662. https://doi.org/10.1186/s12967-023-04537-1.

Ye Y, Jia X, Bajaj M, Birnbaum Y. Dapagliflozin attenuates Na(+)/H(+) exchanger-1 in cardiofibroblasts via AMPK activation. Cardiovasc Drugs Ther. 2018;32(6):553–8. https://doi.org/10.1007/s10557-018-6837-3.

Wang X, Chen X, Dobrev D, Li N. The crosstalk between cardiomyocyte calcium and inflammasome signaling pathways in atrial fibrillation. Pflugers Arch. 2021;473(3):389–405. https://doi.org/10.1007/s00424-021-02515-4.

Hui Y, Junzhu C, Jianhua Z. Gap junction and Na+-H+ exchanger alternations in fibrillating and failing atrium. Int J Cardiol. 2008;128(1):147–9.

Jayachandran JV, Zipes DP, Weksler J, Olgin JE. Role of the Na(+)/H(+) exchanger in short-term atrial electrophysiological remodeling. Circulation. 2000;101(15):1861–6. https://doi.org/10.1161/01.cir.101.15.1861.

Bertero E, Prates Roma L, Ameri P, Maack C. Cardiac effects of SGLT2 inhibitors: the sodium hypothesis. Cardiovasc Res. 2018;114(1):12–8. https://doi.org/10.1093/cvr/cvx149.

Gao J, Xue G, Zhan G, et al. Benefits of SGLT2 inhibitors in arrhythmias. Front Cardiovasc Med. 2022;9:1011429. https://doi.org/10.3389/fcvm.2022.1011429.

Peng X, Li L, Zhang M, et al. Sodium-glucose cotransporter 2 inhibitors potentially prevent atrial fibrillation by ameliorating ion handling and mitochondrial dysfunction. Front Physiol. 2020;11:912. https://doi.org/10.3389/fphys.2020.00912.

Lee K, Lee SK, Lee J, et al. Protocol of BEYOND trial: Clinical BEnefit of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in rhYthm cONtrol of atrial fibrillation in patients with diabetes mellitus. PLoS One. 2023;18(1):e0280359. https://doi.org/10.1371/journal.pone.0280359.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

1-3

Thông tin tác giả